ChemGenex To Present Pivotal Data In T315I Positive CML Patients As Oral Presentation At ASCO

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Clinical Trials / Drug Trials;  Cancer / Oncology
Article Date: 18 May 2009 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral presentation at the forthcoming American Society of Clinical Oncology (ASCO) 45th Annual Meeting in Orlando, Florida.

Data from the pivotal study on the use of omacetaxine in chronic myeloid leukemia (CML) patients who have failed imatinib and who harbor the T315I mutation, will be given at 11:30 am on Monday 1st June, by Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center.

In addition, a poster on the company's complementary phase 2 study investigating the potential use of omacetaxine in CML patients with resistance to multiple tyrosine kinase inhibitors (TKIs), will be presented between 5-6 pm on Friday 29th May by Dr. Meir Wetzler MD, Chief of the Division of Leukemia, School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park Cancer Institute.

Commenting on today's publication of the final program for ASCO, Greg Collier, Ph.D., Managing Director and Chief Executive Officer of ChemGenex said, "We are delighted that our late stage product candidate, omacetaxine, will be presented at a podium session during this prestigious conference."

About Omacetaxine

Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously.

Source
ChemGenex Pharmaceuticals Limited